Journals By Industry - Lipid Lowering Agents

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/a40950/market_and_product) has announced the addition of the "Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor" report to their offering. The industry is bracing...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/2458e4/myocardial_infarct) has announced the addition of GlobalData 's new report "Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. GlobalData, the industry...

Not had time to read the journals? Let Dr Louise Newson bring you up to date on the latest research. - Bisphosphonates may be beneficial before knee and hip replacements BMJ 2011; 343:...

The Phase III study was a single-arm, open label trial, designed to evaluate the efficacy and long-term safety of lomitapide for the treatment of patients with homozygous familial hypercholesterolemia, or HoFH. The data...

While many San Diego companies were taking it slow in the weeks leading up to 2012, Carmel Valley-based biopharmaceutical firm Santarus Inc. was taking action on plans to expand its product portfolio. The...

ALN-PCS demonstrated statistically significant RNAi silencing of PCSK9 of up to 66% and reductions of up to over 50% in levels of low-density lipoprotein cholesterol, or LDL-C, or bad cholesterol, a clinically validated...

- RNAi Therapeutic Achieves Robust Silencing of PCKS9 and Reductions of Over 50% in LDL Cholesterol, a Validated Clinical Endpoint - - Results Highlight Major Potency Improvements of Second-Generation Lipid Nanoparticle Platform in...

Out of 240 branded pharma websites, only about a fifth have any African American imagery on their pages, and bilingual sections of pharma sites are often missing important elements like the "Questions to...

Copycat versions of Pfizer's Lipitor could capture more than half the market for the cholesterol-lowering drug while taking share from other statins, analysts predict. Generic atorvastatin made its debut Nov. 30, and analysts...

Company Profiles Leading Local Companies Strengths The world's largest drugmakers in terms of revenue. A focus on R&D to drive growth. Weaknesses Loss of patent protection for Lipitor (atorvastatin) in the US during...

Strengths One of the leading foreign pharmaceutical companies in Serbia. Extensive range of prescription medicines, as well as OTCs and animal health products. Long history of involvement in the Serbian market. Weaknesses Strong...

Strengths...

Multinational Companies...

Company Monitor Indigenous Companies Strengths Strong position in its core markets of the Czech Republic and Slovakia, with growth targeted in Romania. The acquisition of Sicomed in Romania in late 2005 provided a...

Strengths One of the leading regional players. Krka's leading market is South East Europe, which covers Croatia. Strong generic medicines portfolio. Considerable local market knowledge and experience and direct manufacturing presence. Weaknesses Downward...

Multinational Companies Overview Pfizer is the leading pharmaceutical company in Thailand, a position attained following the acquisition of Pharmacia, and strengthened with the 2009 take-over of Wyeth. The company provides sales, marketing, medical,...

Company Monitor Local Manufacturers SWOT Analysis Strengths Significant product portfolio, with an estimated 6.5% market share in 2008.Solid presence in distribution ensures high margins and efficiency.The acquisition of BMS's local plant in Argentina...

SWOT Analysis Strengths Strong international presence based on its diversified regional presence, with manufacturing facilities in Chile and a subsidiary in Mexico.Bagó holds local co-marketing arrangements with leading research-based foreign players.As an Argentine...

SWOT Analysis Strengths...